Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sanofi : mRNA COVID-19 Jab Candidate Shows Positive Results in Phase 1/2 Study

09/28/2021 | 02:27am EST


ę MT Newswires 2021
All news about SANOFI
12/08Sanofi-Regeneron's Asthma Drug Lowers Severe Attacks Among Children In Late-Stage Study
MT
12/07Top Intellectual Property Issues To Watch In 2022
AQ
12/07SANOFI : Jefferies reiterates its Buy rating
MD
12/06VACCINES INVESTOR EVENT : Sanofi reiterates confidence in strong growth outlook and showca..
PU
12/06Odyssey buys drugmaker BenevolentAI in Europe's biggest SPAC deal
RE
12/06SANOFI : EMA accepts regulatory submission for olipudase alfa, the first potential therapy..
PU
12/06Success For Sanofi And Rouse
AQ
12/03SANOFI : Deutsche Bank reaffirms its Sell rating
MD
12/02Vaccines Investor Event, Sanofi reiterates confidence in strong growth outlook and show..
AQ
12/02SANOFI : Receives a Buy rating from Kepler Cheuvreux
MD
More news
Analyst Recommendations on SANOFI
More recommendations
Financials
Sales 2021 37 727 M 42 750 M 42 750 M
Net income 2021 6 207 M 7 034 M 7 034 M
Net Debt 2021 9 762 M 11 062 M 11 062 M
P/E ratio 2021 17,3x
Yield 2021 3,91%
Capitalization 106 B 120 B 120 B
EV / Sales 2021 3,07x
EV / Sales 2022 2,81x
Nbr of Employees 99 412
Free-Float 88,4%
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 84,60 €
Average target price 107,07 €
Spread / Average Target 26,6%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Chairman
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capi. (M$)
SANOFI7.50%120 365
JOHNSON & JOHNSON3.80%430 061
ROCHE HOLDING AG19.17%324 115
PFIZER, INC.39.85%290 297
NOVO NORDISK A/S70.26%250 392
ELI LILLY AND COMPANY45.17%222 215